 |
|
|
|
 |
|
|
| Article 1 to 10 out of 15 concerning Lexicon Pharmaceuticals, Inc.
|
-
Nuevolution Announces Drug Discovery Alliance with Lexicon Pharmaceuticals
(06/12/2008)
Nuevolution A/S announced a strategic alliance with Lexicon Pharmaceuticals, Inc. aimed at the discovery of novel small molecule lead compounds for highly validated drug targets.Under the terms of the alliance, Nuevolution's proprietary Chemetics® ...
-
Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
(06/12/2007)
Lexicon Pharmaceuticals, Inc. announced the publication of new findings from a joint research project with scientists at Fox Chase Cancer Center in Philadelphia, PA. Together with David L. Wiest, Ph.D., Lexicon researchers have discovered a novel ...
-
Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
(04/20/2007)
Lexicon Genetics Incorporated announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, ...
-
Lexicon Genetics changes name and refocuses business
(01/31/2007)
Refocusing Business to Achieve Goal of Advancing Ten Drug Candidates into Human Clinical Trials by 2010
Lexicon Genetics Incorporated announced that it is changing its name to Lexicon Pharmaceuticals, Inc. to reflect that it is focusing its operations on drug discovery and development activities related to its 10to10 Program. The 10to10 Program is an ...
-
Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome
(01/26/2007)
Lexicon Genetics Incorporated announced that it has initiated Phase 1 clinical trials of LX1031, its oral drug candidate for irritable bowel syndrome (IBS) and other gastrointestinal disorders. Irritable bowel syndrome is a common gastrointestinal ...
-
Lexicon Genetics Awarded Additional Grant for Study of Spinal Muscular Atrophy
(10/13/2006)
Lexicon Genetics Incorporated announced that its research program to identify targets that may be important in the development of drugs to prevent or treat spinal muscular atrophy (SMA) has been extended for an additional year by the United States ...
-
Lexicon Genetics Awarded Funding from DARPA to Identify Drug Targets with Potential for Improving Sleep-Related Performance
(09/28/2006)
Lexicon Genetics Incorporated announced that it was awarded funding from the United States Defense Advanced Research Projects Agency (DARPA) for the identification of targets that may be important in the development of drugs to enhance the ...
-
Lexicon Genetics Granted Exclusive License to Cellectis' Homologous Recombination Technology
(07/14/2006)
Lexicon Genetics Incorporated announced that Cellectis SA has granted Lexicon an exclusive, worldwide license under the patents and patent applications covering Cellectis' technology for the specific replacement or insertion of a gene in a ...
-
Bristol-Myers Squibb Extends Neuroscience Alliance with Lexicon Genetics
(06/06/2006)
Lexicon Genetics Incorporated announced that Bristol-Myers Squibb Company has extended the target discovery term of its neuroscience alliance with Lexicon for an additional two years. Bristol-Myers Squibb and Lexicon initiated this alliance in ...
-
Lexicon Genetics Awarded Grant from the United States Army for Study of Spinal Muscular Atrophy
(05/15/2006)
Lexicon Genetics Incorporated announced that it was awarded a grant from the United States Army Medical Research & Materiel Command (USAMRMC) for the identification of targets that may be important in the development of drugs to prevent or treat ...
Additional information
Lexicon Pharmaceuticals, Inc.
The Woodlands, TX, United States of America
Company
|
|
|
|
|
|
Top
